• Je něco špatně v tomto záznamu ?

Chronic rhinosinusitis and extraesophageal reflux: Who is the candidate for antireflux treatment

K. Zeleník, M. Formánek, P. Matoušek, P. Komínek,

. 2016 ; 30 (2) : e5-9.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000342

BACKGROUND: During the past decade, extraesophageal reflux (EER) has been hypothesized to be one of the possible factors that contribute to the worsening of chronic rhinosinusitis (CRS). However, the relationship remains indeterminate due to its complexity, and it is not clear whether antireflux treatment is indicated for patients with recurrent CRS and who would benefit from it. OBJECTIVE: The aim of the study was to determine the severity of EER in patients with variable durations of CRS and different numbers of previous endoscopic endonasal surgeries (EES). METHODS: Ninety patients with CRS were recruited for the prospective case series. The age, sex, body mass index, reflux symptom index, duration of treatment of CRS with corticosteroids, and the number of ESS within the previous 5 years were ascertained. The severity of EER was evaluated by oropharyngeal pH monitoring by using the Restech system (the presence of EER, value of the RYAN score) and compared among the groups with varying durations of treatment of CRS (≤10 years, 11-20 years, >20 years) and different numbers of ESS within the previous 5 years (no ESS, 1-2 ESS, >2 ESS). RESULTS: Pathologic EER was present significantly more often in patients with CRS treated for >10 years (p = 0.0054) and in patients who underwent >2 ESS within the previous 5 years (p = 0.0001). CONCLUSION: Patients with CRS treated for >10 years and those who had undergone >2 ESS within the previous 5 years had significant EER. Antireflux therapy (e.g., proton pump inhibitors) can be recommended for these patients. However, its effect has to be confirmed in further studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000342
003      
CZ-PrNML
005      
20250422080752.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.2500/ajra.2016.30.4286 $2 doi
024    7_
$a 10.2500/ajra.2016.30.4286 $2 doi
035    __
$a (PubMed)26980378
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zeleník, Karol $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Ostrava, Ostrava, Czech Republic.
245    10
$a Chronic rhinosinusitis and extraesophageal reflux: Who is the candidate for antireflux treatment / $c K. Zeleník, M. Formánek, P. Matoušek, P. Komínek,
520    9_
$a BACKGROUND: During the past decade, extraesophageal reflux (EER) has been hypothesized to be one of the possible factors that contribute to the worsening of chronic rhinosinusitis (CRS). However, the relationship remains indeterminate due to its complexity, and it is not clear whether antireflux treatment is indicated for patients with recurrent CRS and who would benefit from it. OBJECTIVE: The aim of the study was to determine the severity of EER in patients with variable durations of CRS and different numbers of previous endoscopic endonasal surgeries (EES). METHODS: Ninety patients with CRS were recruited for the prospective case series. The age, sex, body mass index, reflux symptom index, duration of treatment of CRS with corticosteroids, and the number of ESS within the previous 5 years were ascertained. The severity of EER was evaluated by oropharyngeal pH monitoring by using the Restech system (the presence of EER, value of the RYAN score) and compared among the groups with varying durations of treatment of CRS (≤10 years, 11-20 years, >20 years) and different numbers of ESS within the previous 5 years (no ESS, 1-2 ESS, >2 ESS). RESULTS: Pathologic EER was present significantly more often in patients with CRS treated for >10 years (p = 0.0054) and in patients who underwent >2 ESS within the previous 5 years (p = 0.0001). CONCLUSION: Patients with CRS treated for >10 years and those who had undergone >2 ESS within the previous 5 years had significant EER. Antireflux therapy (e.g., proton pump inhibitors) can be recommended for these patients. However, its effect has to be confirmed in further studies.
650    _2
$a dospělí $7 D000328
650    _2
$a chronická nemoc $7 D002908
650    _2
$a progrese nemoci $7 D018450
650    12
$a endoskopie $7 D004724
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a gastroezofageální reflux $x farmakoterapie $x epidemiologie $x chirurgie $7 D005764
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a inhibitory protonové pumpy $x terapeutické užití $7 D054328
650    _2
$a rýma $x farmakoterapie $x epidemiologie $x chirurgie $7 D012220
650    12
$a rinoplastika $7 D012225
650    _2
$a sinusitida $x farmakoterapie $x epidemiologie $x chirurgie $7 D012852
655    _2
$a časopisecké články $7 D016428
700    1_
$a Formánek, Martin
700    1_
$a Matoušek, Petr, $d 1973- $7 xx0068189
700    1_
$a Komínek, Pavel
773    0_
$w MED00190544 $t American journal of rhinology & allergy $x 1945-8932 $g Roč. 30, č. 2 (2016), s. e5-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26980378 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20250422080753 $b ABA008
999    __
$a ok $b bmc $g 1179482 $s 960909
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 2 $d e5-9 $i 1945-8932 $m American journal of rhinology & allergy $n Am J Rhinol Allergy $x MED00190544
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...